Vertex Pharmaceuticals is trading 4.17% down at $530.06 as investors weighed mixed third-quarter results. - Revenue reached $3.44 billion, while adjusted EPS of $4.76 missed some analyst estimates; higher costs pressured profitability. - The company raised its full-year revenue outlook to $13.15–$13.25 billion, though the midpoint was below consensus. - Biotech gained 2.13% during the regular session. Reports described a reversal after premarket gains and possible profit-taking following a recent run-up.